Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. lung capacity
Show results for
Products

Companies

News
Articles

Refine by
Date

  • Older

Lung Capacity Articles & Analysis

9 news found

Validating The BLEO-Induced Mouse Model For Drug Discovery

Validating The BLEO-Induced Mouse Model For Drug Discovery

Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the ...

BySCIREQ - an emka TECHNOLOGIES Company


Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

Advancing Tuberculosis Treatment: The Role of flexiVent In Evaluating Bacteriophage Therapy

The rise of antibiotic-resistant bacteria has driven renewed interest in alternative treatments, including phage therapy. A recent study by Yang, F., et al (2024) explores the potential of bacteriophage therapy for treating multi-drug resistant Mycobacterium tuberculosis (Mtb) infections using humanized mouse models. This study highlights the efficacy of phage DS6A in reducing Mtb load ...

BySCIREQ - an emka TECHNOLOGIES Company


Studying Flow-Induced Pulmonary Hypertension and Compensatory Lung Growth: Insights from A Novel Murine Model

Studying Flow-Induced Pulmonary Hypertension and Compensatory Lung Growth: Insights from A Novel Murine Model

In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its ...

BySCIREQ - an emka TECHNOLOGIES Company


Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

The Zephyr Valve is a minimally invasive treatment option that can deliver significant benefits to patients including improvements in lung function, exercise capacity, and quality of life.1 Placed by bronchoscopy, with no cutting or incision, the valves are for patients who remain symptomatic despite optimal management including medications, pulmonary ...

ByPulmonx Corporation


Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics

Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics

Our differentiated device technology platform has the potential to simplify the delivery of higher efficiency inhalation drug products, making effective therapies available for patients with compromised lung function.” About Nob Hill Therapeutics: Nob Hill Therapeutics patented DryNeb™ Dry Powder Nebulizer is proven to deliver treatment drugs to the lower respiratory ...

ByNob Hill Therapeutics


Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

The SBIR grant award further validates the potential benefit of this delivery technology to develop therapies to treat severe lung infections.” “This grant is built on our successful phase I grant work conducted a year ago, which delivered encouraging animal efficacy study results. ...

ByNob Hill Therapeutics


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

In addition to greatly reducing severe asthma attacks and improving lung function, patients in our clinical trials also reduced their oral corticosteroid use. ...

ByRegeneron Pharmaceuticals Inc.


FRI: In The transition from Research to Clinical Practice

FRI: In The transition from Research to Clinical Practice

It is not inconceivable that we will stop conducting lung function tests and perform a CT scan instead to determine lung capacity, residual volume, flow characteristics, and emphysema score. ...

ByFluidda


IAQ Marketing Specialist Reveals his Personal Fight with Mold

IAQ Marketing Specialist Reveals his Personal Fight with Mold

Fears of a potential heart attack were quickly dismissed and replaced by new concerns over a growth discovered on his lung. The article discusses the process of discovery that lead to a diagnosis of a fungal infection from Coccidioides immitis. The infection reduced the 39 year old’s lung capacity to that of a 72 year old and lead to a ...

ByCochrane & Associates, LLC

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT